Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 GSK, Actelion Partner on Insomnia Drug | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

GSK, Actelion Partner on Insomnia Drug

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Actelion has signed an agreement with GSK valued at as much as $3.3 billion to jointly develop and market Actelion’s experimental sleeping pill candidate, almorexant. Actelion will receive an upfront payment of $148 million and $409 million upon registration of the drug. Actelion is also eligible to receive as much as $2.7 billion in success-based milestones, as well as royalties. Under the agreement, GSK will receive exclusive worldwide rights, excluding Japan, to co-develop and co-commercialize the drug.
   
Results from a late stage-trial investigating almorexant’s safety and efficacy in insomnia patients are expected in 2009. Current data suggests the drug helps insomniacs fall and stay asleep in a nonsedative fashion.
   
Actelion will continue to lead the development program and potential registration for almorexant in the first indication, primary insomnia, with GSK contributing 40% of the costs. Almorexant will also be studied in other orexin-related disorders and all costs and profits related to these programs will be shared equally.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters